PTSDAnxiety DisordersObsessive-Compulsive Disorder (OCD)Substance Use Disorders (SUD)Palliative & End-of-Life DistressDepressive DisordersLSDPsilocybin

LSD treatment in Scandinavia: emphasizing indications and short-term treatment outcomes of 151 patients in Denmark

This retrospective follow-up study (n=151) assessed the case material of 151 patients who applied for financial compensation for harms elicited by psychedelic treatments administered between 1959 to 1973 and re-evaluated in 1986. It found that one-third of the patients experienced a transient improvement in their mental state independent of the diagnosis, while the mental state of another third of the patients deteriorated with treatment.

Authors

  • Larsen, J. K.

Published

Nordic Journal of Psychiatry
individual Study

Abstract

Background

New research has suggested the clinical use of lysergic acid diethylamide (LSD) and psilocybin in selected patient populations. However, concerns about the clinical use of LSD were advanced in a large Danish follow-up study that assessed 151 LSD-treated psychiatric patients approximately 25 years after their treatment in the 1960s.

Aims

The purpose of the present study was to give a retrospective account of the short-term outcome of LSD treatment in these 151 Danish psychiatric patients.

Methods

The LSD case material in the Danish State Archives consists of medical case records of 151 LSD-treated patients, who complained and received economic compensation with the LSD Damages Law. The author carefully read and reviewed the LSD case material.

Results

LSD was used to treat a wide spectrum of mental disorders. Independent of diagnoses, 52 patients improved, and 48 patients worsened acutely with the LSD treatment. In a subgroup of 82 neurotic patients, the LSD dose-index (number of treatments multiplied by the maximal LSD dose) indicated the risk of acute worsening. In another subgroup of 19 patients with obsessive-compulsive neurosis, five patients later underwent psychosurgery. A small subgroup of 12 patients was treated with psilocybin. The long-term outcome was poor in most of the patients.

Conclusions

Despite the significant limitations to a retrospective design, this database warrants caution in mental health patients. The use of LSD and psilocybin in mental health patients may be associated with serious short- and long-term side effects. Until further trials with rigorous designs have cleared these drugs of their potential harms, their clinical utility in these groups of patients has not been fully clarified.

Available with Blossom Pro

Research Summary of 'LSD treatment in Scandinavia: emphasizing indications and short-term treatment outcomes of 151 patients in Denmark'

Introduction

Larsen frames the study against a renewed interest in psychedelics such as LSD and psilocybin for hard-to-treat conditions (for example, end-of-life anxiety, addiction and PTSD) and mentions contemporary positive, small open-label and review studies suggesting therapeutic potential under strict safeguards. At the same time, he notes historical concerns about harms following clinical LSD use and refers to his prior long-term Danish follow-up of 151 patients treated in the 1960s, which found worrying long-term sequelae including frequent flashbacks. The present paper aims to provide a retrospective account of the short-term (acute) outcomes of LSD treatment in those same 151 Danish psychiatric patients, estimating potential beneficial and damaging effects. Larsen positions this as an analysis of archival case material held under the Danish LSD Damages Law to better characterise immediate treatment effects and possible dose–response relationships in this historical clinical cohort.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Study Details

References (10)

Papers cited by this study that are also in Blossom

Psychedelic medicine: a re-emerging therapeutic paradigm

Tupper, K. W., Wood, E., Yensen, R. et al. · Canadian Medical Association Journal (2015)

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)

1174 cited
Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)

Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population

Hendricks, P. S., Thorne, C. B., Clark, B. et al. · Journal of Psychopharmacology (2015)

345 cited
Lysergic acid diethylamide: side effects and complications

Cohen, S. · Journal of Nervous and Mental Disease (1980)

Adverse Reactions to Psychedelic Drugs - A Review of the Literature

Strassman, R. J. · Journal of Nervous and Mental Disease (1984)

273 cited
Psychedelics and mental health: a population study

Krebs, T. S., Johansen, P. ˚. Ø. · PLOS ONE (2013)

Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases

Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)

594 cited

Cited By (1)

Papers in Blossom that reference this study

Therapeutic uses of psychedelics for eating disorders and body dysmorphic disorder

Ledwos, N., Rodas, J. D., Husain, M. I. et al. · Journal of Psychopharmacology (2022)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

LSD treatment in Scandinavia: emphasizing... — Research Summary & Context | Blossom